CRP

Crystal Pro Aims to Become the first Crypto-based Platform in Indonesia Streamlining Business Operations

Retrieved on: 
星期一, 八月 16, 2021
Crypto, SMART, Ecosystem, Crystal, Entrepreneurship, Advertising, CRYSTAL, Decentralized finance, Treasury, Marketing, Technology, CRP, ICO, MSME-Champions, BNB, Industry, NFT, Cryptocurrency

JAKARTA, Indonesia, Aug. 16, 2021 /PRNewswire/ -- Incubated in Indonesia, Crystal Pro is a new generation Crypto Company with the dream to build their blockchain, the way BNB did back in 2009.

Key Points: 
  • JAKARTA, Indonesia, Aug. 16, 2021 /PRNewswire/ -- Incubated in Indonesia, Crystal Pro is a new generation Crypto Company with the dream to build their blockchain, the way BNB did back in 2009.
  • The company is eagerly looking forward to linking the enterprise and financial sectors to launch economic integration schemes.
  • The CRYSTAL PRO COIN blockchain has a network of the private and public sectors to ease the overall process.
  • Their token will be called the Crystal Pro coin called $SCRP (SMART CRYSTALPRO) and will convert from $CRP to $SCRP.

Humanigen Reports Second Quarter 2021 Financial Results

Retrieved on: 
星期四, 八月 12, 2021
Biotechnology, Pharmaceutical, Health, Clinical Trials, CFO, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Trial of the century, European Directorate for the Quality of Medicines & HealthCare, Holocene, European Medicines Agency, COVID, Achievement, EUA, Marketing, MD, COVID-19, MAA, COO, FDA, Patient, Telcon, CRP, Health, Nasdaq, MHRA, Review, Pharmaceutical industry

Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate, lenzilumab, today provided a corporate and regulatory update and reported financial results for the second quarter and six months ended June 30, 2021.

Key Points: 
  • Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate, lenzilumab, today provided a corporate and regulatory update and reported financial results for the second quarter and six months ended June 30, 2021.
  • Second Quarter and Recent Highlights:
    Submitted an application to the FDA for an EUA for lenzilumab for the treatment of patients hospitalized with COVID-19.
  • Second Quarter and Six Months Ended June 30, 2021 Financial Results
    Net loss for the three months ended June 30, 2021 was $70.8 million or $1.20 per share as compared to $24.0 million or $0.79 per share for the three months ended June 30, 2020.
  • For the third quarter of 2021 the company anticipates the R&D expense related to lenzilumab production will be same level as the second quarter of 2021.

Applied Molecular Transport Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
星期二, 八月 10, 2021
UC, Autoimmunity, GI, CRP, Inflammation, IE, Therapy, R, G&A, Patient, Histology, Rheumatoid arthritis, Biology, Calprotectin, U.S. Securities and Exchange Commission, GMP, Technology, Security (finance), Securities Exchange Act of 1934, Ulcerative colitis, Terminology, Securities Act of 1933, Nasdaq, AMTI, AMT, SEC, Investment, Disease, GLOBE, CA, Microbiome, Growth, Magazine, Inflammatory Bowel Diseases, Epithelium, Pharmaceutical industry, Cryptocurrency, Medical device, Fine chemical

SOUTH SAN FRANCISCO, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today provided a corporate update and reported financial results for the second quarter ended June 30, 2021.

Key Points: 
  • Total R&D expenses for the second quarter of 2021 were $16.5 million, compared to $12.8 million for the same period in 2020.
  • Total G&A expenses for the second quarter of 2021 were $7.1 million, compared to $2.5 million for the same period in 2020.
  • Net loss for the second quarter of 2021 was $23.6 million, compared to $15.4 million for the same period in 2020.
  • Active transport is an efficient mechanism that uses the cells own machinery to transport materials across the IE barrier.

Invitation to presentation of Cantargia's report for the second quarter of 2021 on August 19 at 3.00 p.m. CET

Retrieved on: 
星期二, 八月 10, 2021
FOLFIRINOX, Biomarker, CRP, Pancreatic cancer, IL1RAP, NSCLC, Patient, PDAC, ASCO, IL-6, Safety, Large-cell lung carcinoma, Myocarditis, Biotechnology, ADCC, File system, Nasdaq Stockholm, Pharmaceutical industry

556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases.

Key Points: 
  • 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases.
  • The basis for this is the protein IL1RAP that is involved in a number of diseases and where Cantargia has established a platform.
  • Positive interim data from the combination with chemotherapy indicate stronger efficacy than would be expected from chemotherapy alone.
  • Cantargia's second project, the antibody CAN10, addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on systemic sclerosis and myocarditis.

Lenzilumab Treatment May Provide Enhanced Likelihood of Survival Without Ventilation in Hospitalized Black and African-American COVID-19 Patients

Retrieved on: 
星期三, 八月 4, 2021
Health, Infectious Diseases, Hospitals, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Clinical medicine, Medical specialties, Medicine, Biomarkers, C-reactive protein, Chemical pathology, CAMP receptor protein, CRP Group, the LIVE-AIR, Phase 3 Study of Lenzilumab, Humanigen, Inc., THE LIVE-AIR, PHASE 3 STUDY OF LENZILUMAB, HUMANIGEN, INC.

In the overall population with CRP

Key Points: 
  • In the overall population with CRP
  • LIVE-AIR Phase 3 study met its primary endpoint of survival without ventilation demonstrating a 1.54-fold improvement overall and trended to a 2.68-fold improvement in Black and African-American patients.
  • This study was a randomized, double-blind, placebo-controlled, multi-center Phase 3 trial for the treatment and prevention of serious and potentially fatal outcomes in patients hospitalized with COVID-19 pneumonia.
  • The primary endpoint was the difference between lenzilumab treatment and placebo treatment in SWOV through day 28 following treatment.

Bulbrite's Cathy Choi Receives 2021 ALA Women in Lighting Leadership Award

Retrieved on: 
星期四, 七月 15, 2021
Goddesses, Ala, Deities

DALLAS, July 15, 2021 /PRNewswire/ --Bulbrite President Cathy Choi of Moonachi, N.J., is the 2021 recipient of the American Lighting Association (ALA) Women in Lighting Leadership Award (WILLA).

Key Points: 
  • DALLAS, July 15, 2021 /PRNewswire/ --Bulbrite President Cathy Choi of Moonachi, N.J., is the 2021 recipient of the American Lighting Association (ALA) Women in Lighting Leadership Award (WILLA).
  • The WILLArecognizes one woman annually for her achievement and leadership in the lighting industry, support of ALA, mentoring of other women in the industry, and devotion to her community through philanthropy and volunteer work.
  • The recipient must be a member of ALA, nominated by an ALA member, and voted upon by the Women in Lighting Committee.
  • Nominations for the Women in Lighting Leadership Award are accepted year-round at lightingwomen.com , where additional information about the award and organization is available.

Veritone Continues International Expansion Through Agreement with Peru’s CRP Radios

Retrieved on: 
星期二, 二月 9, 2021
Technology, Entertainment, Security, Other Technology, Advertising, Communications, Audio, Video, Software, TV and Radio, Clinical medicine, Medicine, Veritone, Medical specialties, CRP, C-reactive protein, Commercial Radio Hong Kong, Veritone, CRP Media

Veritone , Inc. (Nasdaq: VERI), the creator of the worlds first operating system for artificial intelligence, aiWARE , today announced a new agreement with Lima, Peru-based commercial radio group, CRP Radios .

Key Points: 
  • Veritone , Inc. (Nasdaq: VERI), the creator of the worlds first operating system for artificial intelligence, aiWARE , today announced a new agreement with Lima, Peru-based commercial radio group, CRP Radios .
  • View the full release here: https://www.businesswire.com/news/home/20210209005312/en/
    Veritone's agreement with Peru's CRP Radios continues the company's international expansion.
  • (Photo: Business Wire)
    The agreement allows CRP Radios to leverage Veritone Attribute , a leading AI-enabled broadcast attribution application, giving the group greater insight into ad performance across its eight radio stations.
  • Through the use of Veritone Attribute, CRP Radios will also be able to show the efficacy of the campaign, inform ad optimization strategies and maximize return on investment for advertisers.

Marsh and Construction Risk Partners Agree to Separate

Retrieved on: 
星期四, 九月 5, 2019
Insurance, Urban planning, Finance, REIT, Landscape, Interior design, Building Systems, Other Construction & Property, Professional services, Architecture, Residential Building & Real Estate, Commercial Building & Real Estate, Construction & Property, Economy, Finance, Money, Marsh & McLennan Companies, Marsh, Insurance broker, General contractor, Insurance, Jardine Lloyd Thompson, Marsh, CRP

Marsh, the worlds leading insurance broker and risk adviser, and Construction Risk Partners (CRP), a leading specialty broker dedicated to the US construction industry, today announced that they have entered an agreement whereby CRP management will buy back the companys stock from JLT Specialty USA.

Key Points: 
  • Marsh, the worlds leading insurance broker and risk adviser, and Construction Risk Partners (CRP), a leading specialty broker dedicated to the US construction industry, today announced that they have entered an agreement whereby CRP management will buy back the companys stock from JLT Specialty USA.
  • Rob McDonough, US Construction Practice Leader, Marsh JLT Specialty, added: Marsh will continue to serve construction clients through the more than 600 construction experts across the US who provide advice, risk transfer solutions, and claims advocacy to more than 2,000 contractors and subcontractors.
  • Marsh is a wholly owned subsidiary of Marsh & McLennan Companies NYSE: MMC), the leading global professional services firm in the areas of risk, strategy and people.
  • Construction Risk Partners is a leading specialty broker dedicated to the construction industry with over 90 employees and six offices throughout the country.

C-Reactive Protein Testing Market Size Worth $1.77 Billion by 2025: Grand View Research, Inc.

Retrieved on: 
星期四, 四月 19, 2018
Medicine, Clinical medicine, Blood tests, Immunologic tests, Intensive care medicine, Biomarkers, C-reactive protein, Cardiovascular disease, CRP

The global c-reactive protein (CRP) testing market size is expected to reach USD 1.77 billion by 2025, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 1.3% during the forecast period.

Key Points: 
  • The global c-reactive protein (CRP) testing market size is expected to reach USD 1.77 billion by 2025, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 1.3% during the forecast period.
  • Rising incidence of inflammatory disorders such as cancer infections and cardiovascular disorders is one of the leading factors driving market growth.
  • Furthermore, increasing global incidence of endometriosis in women is expected to play a major role in the CRP testing market over the forecast period.
  • Grand View Research has segmented the global C-reactive protein testing market on the basis of assay type, detection range, disease area, end use, and region:
    C-Reactive Protein Testing Assay Type Outlook(Revenue, USD Million, 2014 - 2025)